Nemes Laszlo/iStock via Getty Images Syros Pharmaceuticals ( NASDAQ: SYRS ) will discontinue enrollment in a phase 2 trial of its acute myeloid leukemia drug tamibarotene in combination with Venclexta (venetoclax) and Vidaza (azacitidine) due to poor results from an interim analysis. A similar complete response rate was seen in the triplet arm as well as the arm with patients receiving only Venclexta and Vidaza. "As a result, the probability for success of the SELECT-AML-1 study to demonstrate superiority at the final analysis in 80 randomized patients was considered low," the company said.
Syros said those currently taking part in the trial will have the opportunity to continue if study investigators approve. Chief Medical Officer David Roth said that another phase 2 study looking at a combination of tamibarotene and Vidaza showed a 61% CR rate in newly diagnosed AML patients with RARA overexpression. "This supports our conviction in pursuing a doublet strategy in higher-risk [myelodysplastic syndromes], where we are comparing tamibarotene and azacitidine to azacitidine alone.
" Phase 3 trial results of tamibarotene and Vidaza in MDS is expected in mid Q4. More on Syros Pharmaceuticals Syros Pharmaceuticals, Inc. (SYRS) Q2 2024 Earnings Call Transcript Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout Syros Pharmaceuticals Q2 2024 Earnings Preview Seeking Alpha’s Quant Rating on Syros Pharmaceuticals Historical earnings data for Syros Pharmaceuticals.
